Centre for Heart Rhythm Disorders (CHRD), University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia.
Pacing Clin Electrophysiol. 2021 Feb;44(2):266-273. doi: 10.1111/pace.14161. Epub 2021 Jan 18.
To characterize contemporary pacemaker procedure trends.
Nationwide analysis of pacemaker procedures and costs between 2008 and 2017 in Australia. The main outcome measures were total, age- and gender-specific implant, replacement, and complication rates, and costs.
Pacemaker implants increased from 12,153 to 17,862. Implantation rates rose from 55.3 to 72.6 per 100,000, a 2.8% annual increase (incidence rate ratio [IRR] 1.028; 95% CI, 1.02-1.04; p < .001). Pacemaker implants in the 80+ age group were 17.37-times higher than the < 50 group (95% CI 16.24-18.59; p < .001), and in males were 1.48-times higher than in females (95% CI 1.42-1.55; p < .001). However, there were similar increases according to age (p = .10) and gender (p = .68) over the study period. Left ventricular lead rates were stable (IRR 0.995; 95% CI 0.98-1.01; p = .53). Generator replacements decreased from 20.5 to 18.3 per 100,000 (IRR 0.975; 95% CI 0.97-0.98; p < .001). Although procedures for generator-related complications were stable (IRR 0.995; 95% CI 0.98-1.01; p = .54), those for lead-related complications decreased (IRR 0.985; 95% CI 0.98-0.99; p < .001). Rates for all pacemaker procedures were consistently greater in males (p < .001). Although annual costs of all pacemaker procedures increased from $178 million to $329 million, inflation-adjusted costs were more stable, rising from $294 million to $329 million.
Increasing demand for pacemaker implants is driven by the ageing population and rising rates across all ages, while replacement and complication procedure rates appeared more stable. Males have consistently greater pacemaker procedure rates than females. Our findings have significant clinical and public health implications for healthcare resource planning.
描述当代起搏器程序趋势。
对 2008 年至 2017 年澳大利亚起搏器程序和成本进行全国性分析。主要观察指标为总植入、年龄和性别特异性植入、更换和并发症发生率以及成本。
起搏器植入从 12153 例增加到 17862 例。植入率从 55.3 例/10 万人增加到 72.6 例/10 万人,每年增加 2.8%(发病率比 [IRR]1.028;95%CI,1.02-1.04;p<0.001)。80 岁以上年龄组的起搏器植入率是<50 岁年龄组的 17.37 倍(95%CI 16.24-18.59;p<0.001),男性是女性的 1.48 倍(95%CI 1.42-1.55;p<0.001)。然而,在此研究期间,年龄(p=0.10)和性别(p=0.68)都有相似的增加。左心室导联率保持稳定(IRR 0.995;95%CI 0.98-1.01;p=0.53)。发电机更换从 20.5 例/10 万人减少到 18.3 例/10 万人(IRR 0.975;95%CI 0.97-0.98;p<0.001)。尽管与发电机相关的并发症程序保持稳定(IRR 0.995;95%CI 0.98-1.01;p=0.54),但与导联相关的并发症程序减少(IRR 0.985;95%CI 0.98-0.99;p<0.001)。所有起搏器程序的发生率在男性中始终较高(p<0.001)。尽管所有起搏器程序的年度成本从 1.78 亿美元增加到 3.29 亿美元,但经通胀调整后的成本更为稳定,从 2.94 亿美元增加到 3.29 亿美元。
起搏器植入需求的增加是由人口老龄化和各年龄段植入率上升推动的,而更换和并发症程序率似乎更为稳定。男性的起搏器程序率始终高于女性。我们的研究结果对医疗资源规划具有重要的临床和公共卫生意义。